UOC
CATX icon

UBS O'Connor’s Perspective Therapeutics CATX Stock Holding History

UBS O'Connor’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,060
Closed -$205K – 387
2025
Q1 		$205K Sell
96,060
-27,183
-22% -$81.6K ﹤0.01% 250
2024
Q4 		$393K Buy
123,243
+52,320
+74% +$427K 0.01% 300
2024
Q3 		$947K Sell
70,923
-14,090
-17% -$187K 0.02% 285
2024
Q2 		$848K Buy
+85,013
New +$1.23M 0.02% 316

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's CATX Position: Q2 2025 in Review

UBS O'Connor sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 96,060 shares — an estimated $205K sold.

UBS O'Connor first reported a position in CATX in Q2 2024 and held it in 4 quarters. The position peaked at $947K in Q3 2024. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

  • UBS O'Connor reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 96,060 Perspective Therapeutics shares in Q2 2025, an estimated $205K.
  • UBS O'Connor first reported a position in Perspective Therapeutics in Q2 2024 and held it in 4 quarters.
  • UBS O'Connor's Perspective Therapeutics position peaked at $947K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.